Dr. 马努斯·罗根博士.D, MBA

Manus Rogan博士是bet亚洲365欢迎投注的管理合伙人和联合创始人. He has over 27 years of investment and operating experience in the life science sector in both the US and Europe. Manus earned a PhD in chemistry from the University of York (sponsored by GlaxoSmithKline) and an MBA from Trinity College Dublin.

Manus began his career in product development at GlaxoSmithkline 在美国K and in 1996 joined Elan Corporation’s business development group. For four years he was responsible for licensing products and drug delivery technologies in 欧洲和日本. In 2001, Manus joined Elan’s Corporate Venture Capital group in New York where he invested in private and public biotechnology companies. 投资项目包括Sirna(2006年被默克收购)和Beyond Genomics(2011年IPO)。. 在Elan的7年里, Manus concluded over twenty five investment and technology licensing transactions involving companies 在美国S, 欧洲和日本.

Manus领导了Fountain对Innocoll公司的投资. 目前担任Priothera ltd和Neuromod Devices的董事会成员. He was formerly Chairman of the Irish Venture Capital Association (‘IVCA’) and previously represented Fountain on the boards of Amarin Corporation, Opsona疗法, Inflazome(出售给罗氏), 2020年)和中流砥柱医疗(IPO), 2014).

艾丹·金，MBA, CFA

艾丹•金是bet亚洲365欢迎投注的管理合伙人和联合创始人. Aidan qualified as a pharmacist from Trinity College Dublin and in 1992 joined Elan Corporation’s strategic marketing group with the responsibility of identifying and evaluating product development candidates for Elan’s drug delivery technologies. In 1996, Aidan assumed Head of Strategic Marketing for Elan’s drug delivery division with a focus on competitive analysis and strategic positioning of Elan’s technology platforms.

1998年在都柏林大学学院(University College Dublin)获得MBA学位后，艾丹移居美国.S. 作为Elan公司风险投资集团的创始成员之一. 在接下来的五年里, 艾丹在公共和私人专业制药领域进行了二十多项战略投资, 生物技术和医疗设备公司, 在美国.S.、加拿大和欧洲. 投资包括Quadrant Healthcare(被Elan收购), 2000), Atrix实验室(被QLT收购), 2004), Idun制药公司(被辉瑞收购), 2005年)和新西兰制药公司(IPO), 2010).

In 2004, Aidan加入Bio-IB, 一家总部位于纽约的精品生命科学投资银行，在那里他负责M&A和战略许可交易. 艾丹是CFA持证人. 他目前是Xylocor Therapeutics的董事会成员, Corteria Pharmaceuticals和Ermium Therapeutics. 以前, 他是公司在Syndesi Therapeutics(被Abbvie收购)董事会的代表, 2022), Civitas Therapeutics(被Acorda收购, 2014), 长期的治疗, Velicept Therapeutics和Palyon Medical.

Dr. 埃娜·普罗瑟博士.D.

Dr Ena Prosser is a 合作伙伴 in bet亚洲365欢迎投注 since the initial 基金 raising in 2008 and the two subsequent 基金s. Ena是一名受过培训的生物技术博士，在投资方面有着广泛的背景, 国际联盟及知识产权管理. 她曾领导专业制药公司的技术和产品尽职调查项目, 诊断, 设备和生物技术领域. 在喷泉, Ena领导了几笔投资，包括Genable (Ire) Ltd(2013年出售给Spark Therapeutics Inc)。, led the Series B investment in NeRRe Therapeutics(UK) Ltd and KaNDy Therapeutics (UK) Ltd (acquired by Bayer, 2020), 加入intrem公司董事会.A. 2020年在巴黎，2021年在荷兰的Calypso Biotech.

Ena曾担任爱尔兰企业生物研究爱尔兰董事. 在这个角色中, 她带领了一个庞大的团队去辨认, 基金, 保护和利用有关知识产权, 将生命科学技术商业化，并审查R的投资机会&D.

在加入Enterprise 爱尔兰之前，Ena曾担任多个R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, 授权和收购项目超过9年的期限. Ena has a strong innovation policy background and was a member of the Irish Government Innovation Taskforce in Intellectual Property, ICSTI和爱尔兰知识转移. Ena works closely with leading ophthalmology research charity Fighting Blindness 爱尔兰 and the INFANT Research Center based in UCC (爱尔兰). Ena is an Adjunct Professor at University College Dublin and a member of the Institute of Directors (爱尔兰).

贾斯汀·林奇，MBA

Justin Lynch是bet亚洲365欢迎投注的合伙人. 他于2008年基金I推出前一年加入团队. 贾斯汀有会计学学士学位 & 毕业于都柏林城市大学金融专业, 拥有都柏林三一学院的工商管理硕士学位，是英国特许管理会计师协会的成员. 他在资本市场拥有超过25年的经验, 企业融资, 跨多个行业的创业和风险投资, 后半段是生命科学.

他的职业生涯始于1985年在NCB股票经纪公司担任研究分析师. 在此期间, Justin had analytical responsibility for 13 companies accounting for 25% of the capitalisation of the Irish Stock Exchange. In 1988, Justin joined the Corporate Finance group of Fyffes plc where his activities included the execution of a number of M&A与金融交易. He subsequently held a similar senior Corporate Finance role with the Jones Group plc for several years before returning full time to Trinity College to complete an MBA.

在1997年获得MBA学位后, Justin co-founded Legend Care and developed a series of medical hosiery devices including a preventive foot care device for diabetic foot disease which is presently in a physician led 400 patient longitudinal multi-centre RCT 在美国S and the UK, 由NIDDK资助, 美国国立卫生研究院. 贾斯汀对医疗设备领域特别感兴趣. 他领导公司对Vivasure Medical的投资, Medical Microinstruments (MMI) and Neurent Medical and previously represented Fountain on the board of Neuravi (acquired by J&J, 2017)

我是Ruthanne Monaghan, FCCA

Ruthanne Monaghan is the Chief Financial Officer in bet亚洲365欢迎投注 with responsibility for the finance function, 2020年加入团队. 她拥有超过21年的风险投资经验, 企业融资, 跨多个部门的集团财务和公司治理.

Ruthanne的职业生涯始于IPSI的投资会计师, 并加入Trinity Venture Capital, 2004年成为一家专注于技术的风险投资公司. 她最初担任财务总监，随后担任TVC的投资助理，直到2013年, 参与所有方面的尽职调查, 投资分析与M&一个活动. She was integrally involved in the IPO of TVC in 2007 when the company transitioned to a private equity public company and represented TVC on the boards of Dalata Hotel Group and CR2 Limited.

Ruthanne于2013年加入主流可再生能源，担任高级财务职务, 2015年在Hostelworld Group plc在伦敦和都柏林证券交易所首次公开募股之前加入该公司. 直到2020年，Ruthanne一直是Hostelworld的财务主管, 领导一个大型团队，管理所有上市公司的合规性, 税务筹划及申报, 以及项目管理，团队重组和M&一个集成. 她于2018年担任临时首席财务官，负责投资者关系.

Ruthanne拥有UCD的商业学士学位, 2003年获得ACCA会计师资格，并获得公司秘书法证书 & 从爱尔兰律师协会执业.

塔尼亚·帕科夫斯卡娅博士.D.

Tania Papkovskaia博士是bet亚洲365欢迎投注的高级合伙人. Tania qualified with a BSc in Biochemistry from University College Dublin in 2009 and earned a PhD in Clinical Neuroscience from University College London, sponsored by Eisai Limited in collaboration with the Welcome Trust Consortium and the Institute of Neurology. 她的研究重点是亮氨酸富重复激酶2在帕金森病中的作用. 除了, 她在肿瘤学系进行博士后研究, 剑桥大学, 研究细胞周期蛋白依赖性激酶抑制剂在神经母细胞瘤中的作用.

In 2014, Tania加入了Gerson Lehrman Group的医疗保健团队, 为全球医疗保健投资者提供尽职调查支持, 协调整个制药行业的业务开发工作和产品活动, 生物技术和医疗设备部门. 2017年，她接管了欧洲医疗团队，年薪4美元.500万师, 责任跨越收入, 商业策略, 操作性能, 培训和发展.